We Offer Worldwide Shipping
Login Wishlist

Sodium Aescinate

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-S2019

  • Specification : 98%

  • CAS number : 20977-05-3

  • Formula : C55H85NaO24

  • Molecular Weight : 1153.2

  • PUBCHEM ID : 3084345

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-S2019

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

1153.2

Appearance

White crystalline powder

Botanical Source

herbs of Aesculus hippocastanum L.

Structure Type

Terpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC(C(C)OC(=O)C)C(=O)OCC12C3CC(C(C1O)OC2CC4(C3=CCC5C4(CCC6C5(CCC(C6(C)CO)OC7C(C(C(C(O7)C(=O)O)OC8C(C(C(C(O8)CO)O)O)O)O)OC9C(C(C(CO9)O)O)O)C)C)C)(C)C.[Na+]

Synonyms

3-methyl-pyridine-2-carbonitrile/3-methyl-2-pyridinecarbonitrile/2-cyano-3-methly pyridine/2-cyano-b-picoline/3-methylpyridine-2-carbonitrile/2-Cyano-3-methylpyridine/(h4tes4)[qr]/akrochem tdec/diethyl-carbamodithioicacitetrakis(anhydrosulfide)withthiotelluricac/Sodium escinate

IUPAC Name

sodium;(2S,3S,4S,5R,6R)-6-[[(1R,3S,8S,20S)-22-[(3-acetyloxy-2-methylbutanoyl)oxymethyl]-21-hydroxy-8-(hydroxymethyl)-3,4,8,12,19,19-hexamethyl-23-oxahexacyclo[18.2.1.03,16.04,13.07,12.017,22]tricos-15-en-9-yl]oxy]-4-hydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid

Density

Solubility

Flash Point

Boiling Point

Melting Point

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2933390000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:20977-05-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

26907249

Abstract

Sodium aescinate (SA) is a widely-applied triterpene saponin product derived from horse chestnut seeds, possessing vasoactive and organ-protective activities with oral or injection administration in the clinic. To date, no toxicity or adverse events in SA have been reported, by using routine models (in vivo or in vitro), which are insufficient to predict all aspects of its pharmacological and toxicological actions. In this study, taking advantage of transparent zebrafish larvae (Danio rerio), we evaluated cardiovascular toxicity of SA at doses of 1/10 MNLC, 1/3 MNLC, MNLC and LC10 by yolk sac microinjection. The qualitative and quantitative cardiotoxicity in zebrafish was assessed at 48 h post-SA treatment, using specific phenotypic endpoints: heart rate, heart rhythm, heart malformation, pericardial edema, circulation abnormalities, thrombosis and hemorrhage. The results showed that SA at 1/10 MNLC and above doses could induce obvious cardiac and pericardial malformations, whilst 1/3 MNLC and above doses could induce significant cardiac malfunctions (heart rate and circulation decrease/absence), as compared to untreated or vehicle-treated control groups. Such cardiotoxic manifestations occurred in more than 50% to 100% of all zebrafish treated with SA at MNLC and LC10. Our findings have uncovered the potential cardiotoxicity of SA for the first time, suggesting more attention to the risk of its clinical application. Such a time- and cost-saving zebrafish cardiotoxicity assay is very valid and reliable for rapid prediction of compound toxicity during drug research and development.

KEYWORDS

LC10; MNLC; cardiotoxicity; larvae; sodium aescinate; zebrafish.

Title

In Vivo Cardiotoxicity Induced by Sodium Aescinate in Zebrafish Larvae

Author

Jinfeng Liang 1 , Wangdong Jin 2 , Hongwen Li 3 , Hongcui Liu 4 , Yanfeng Huang 5 , Xiaowen Shan 6 , Chunqi Li 7 8 , Letian Shan 9 , Thomas Efferth 10

Publish date

2016 Feb 23

PMID

28471233

Abstract

Background: Recent studies indicated that insulin resistance may contribute to the pathogenesis of polycystic ovary syndrome (PCOS); however, the specific mechanism is still unclear.
Objective: To investigate the effect of sodium aescinate (SA) on PCOS-IR rat models.
Methods: Sixty rats were randomly divided into the five groups: un-treated rats (n = 12), PCOS-IR group (n = 12), PCOS-IR group plus 50 mg/kg SA (n = 12), PCOS-IR group plus 10 mg/kg SA (n = 12), PCOS-IR group plus 150 mg/kg metformin (n = 12). On day 21, rats were sacrificed, and H(and)E staining was performed for histopathologic examination of the ovaries; moreover, the serum level of follicle-stimulating hormone (FSH), testosterone, and luteotropic hormone (LH) were measured, and the expression as well as phosphorylation of PI3K, Akt and Gsk-3β were examined using western blot assay.
Results: High dosage of SA treatment improved the morphological features of the ovaries in PCOS rats, and also induced significant decrease in serum expression of testosterone and LH/FSH ratio and significant decrease in the expression of p-PI3K, p-Akt and p-Gsk-3β.
Conclusion: Our results demonstrated that SA treatment could alleviate the symptom of PCOS in rat model through regulating the PI3K/Akt/GSK3-β pathway (Fig. 4, Ref. 22).

KEYWORDS

LC10; MNLC; cardiotoxicity; larvae; sodium aescinate; zebrafish.

Title

Effect of Sodium Aescinate Treatment on PCOS Rat Model With Insulin Resistance

Author

L Chen, L M Hu, Y F Wang, H Y Yang, X Y Huang, W Zhou, H X Sun

Publish date

2017

PMID

25903967

Abstract

This study is aimed to evaluate the potential effects of sodium aescinate (SA, the sodium salt of aescin) on wound healing in streptozotocin-induced diabetic rats. An excision skin wound was created in diabetic rats, and the wounded rats were divided into three groups: I) control group, II) gel-treated group, and III) SA-treated group. The control group wounds received topically normal saline once daily for 19 days. The gel-treated and SA-treated wounds received topically 400 μl of pluronic F-127 gel (25%) and 400 μl of SA (0.3%) in pluronic gel, respectively, once daily for 19 days. SA application in diabetic rats increased the wound contraction and significantly decreased the level of the inflammatory cytokine tumor necrosis factor-alpha (TNF-α) in comparison to the gel-treated group and control group. SA application in diabetic rats also resulted in a marked increase in the level of anti-inflammatory cytokine interleukin-10 (IL-10) and activities of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) compared to the other groups. Histopathologically, SA-treated wounds showed better granulation tissue dominated by marked fibroblast proliferation, and wounds were covered by thick regenerated epithelial layer. Additionally, the application of only pluronic gel produced some beneficial effects in some parameters in comparison to control group, but most of them were not significantly different. These findings demonstrated that SA may effectively control and improve wound healing in diabetic rats via its anti-inflammatory and antioxidant activities.

Title

The Efficacy of Sodium Aescinate on Cutaneous Wound Healing in Diabetic Rats

Author

Zonglin Zhang 1 , Guangchao Cao, Liying Sha, Dazhi Wang, Min Liu

Publish date

2015 Oct


Description :

Sodium aescinate is a triterpene saponin derived from Aesculus hippocastanum seeds, with anti-inflammatory and antioxidant activities[1]. Sodium aescinate inhibits hepatocellular carcinoma growth by targeting CARMA3/NF-κB pathway[2].